lundi 3 avril 2017

Onco Actu du 3 avril 2017


5. Traitements

How Cancers Evolve Drug Resistance [The Scientist]

5.10 Traitements - Essais

Draft guideline on multiplicity issues in clinical trials [EMA]

5.12 Immunothérapies

CT Scans May Offer a Non-invasive Alternative to Diagnose Immunotherapy-induced Colitis [AACR]

More Biomarkers Needed for Cancer Immunotherapy [The Scientist]

Neoantigens Enable Personalized Cancer Immunotherapy [The Scientist]

Promising cancer drugs may speed tumours in some patients [Nature]

5.12.1 Immunothérapies - partenariats

Bristol-Myers Squibb and Incyte to Advance the Combination of Opdivo (nivolumab) and Epacadostat into First-line Registrational Trials [BMS]

Merck, Incyte map a Phase III pipeline of their own for a frontline combo of Keytruda and epacadostat [EndPoints]

5.12.2 Immunothérapies - CAR-T

Making CAR T-Cell Therapy Safer [The Scientist]

Kite Pharma hits its Q1 deadline on filing a BLA for its pioneering CAR-T, posts improved data [EndPoints]

5.2 Pharma

Phase III ALUR study supports the use of Roche’s Alecensa for people with advanced ALK-positive lung cancer [Roche]

5.2.3 Pharma - économie

Halozyme dips after pancreatic cancer trial halted for futility [FierceBiotech]

Halozyme slides on an early futility failure for its lead cancer therapy [EndPoints]

5.3.4 Traitements - AMM (FDA, EMA)

IBRANCE® (palbociclib) Receives FDA Regular Approval and Expanded Indication for First-Line HR+, HER2- Metastatic Breast Cancer [Pfizer]

Novartis drug combination Tafinlar® + Mekinist® receives EU approval for BRAF V600-positive advanced non-small cell lung cancer (NSCLC) [Novartis]

FDA Approves New PARP Inhibitor for Ovarian Cancer [Cancer Research Catalyst]

5.9 AACR

Aggressive breast cancer grows faster in obese environment [UNC Lineberger]

Drug combination boost PARP inhibitor response in resistant ovarian cancer [Dana-Farber Cancer Institute]

Beyond genomics: Using proteomics to target tumors [Fred Hutch]

Phase II Copanlisib Data Show Durable Tumor Response in Indolent Non-Hodgkin’s Lymphoma [Bayer]

A ‘sci-fi’ cancer therapy fights brain tumors, study finds [STAT]

Combination HER2-targeted Therapy Effective in Heavily Pretreated HER2-positive Colorectal Cancer Patients [AACR]

Wearable Medical Device Improves Survival for Patients with Glioblastoma [AACR]

Targeted Therapies Selected Based on Multigene Panel Improved Outcomes for Patients with Hard-to-treat Cancers [AACR]

Cancer Type and Mutation Identity Influenced Response to Targeted Therapy in a Basket Clinical Trial [AACR]

6. Lutte contre les cancers

NHS England sets target of 5,000 more people each year surviving cancer [Cancer Research UK]

Contrary to what we are frequently told, we are not “losing the war on cancer” [Science-Based Medicine]

6.1 Observation

Annual Report to the Nation: Cancer death rates continue to decline [NCI]

ASCO Statement on the Annual Report to the Nation on the Status of Cancer, 1975-2014 [ASCO]

US cancer death rates continue to fall as 5-year survival rates rise – study [The Guardian]

6.10.1 Politiques (USA)

Should taxpayers cover the light bills at university labs? Trump kicks off a tense debate [STAT]

6.11 Patients

Cancer patients have 55% greater risk of suicide, study finds [The Guardian]

Cancer patient's family stands to lose £50k under benefit cuts [The Guardian]

6.6 Publications

NIH’s new embrace of preprints will be a boon to science [STAT]